PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
91.74%
Some net income increase while AGEN is negative at -7.26%. John Neff would see a short-term edge over the struggling competitor.
-100.00%
Negative yoy D&A while AGEN is 8.56%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
100.00%
Well above AGEN's 100.31% if it’s a large positive yoy. Michael Burry would see a bigger future tax burden vs. competitor’s approach.
-95.76%
Both cut yoy SBC, with AGEN at -1.90%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
-167.13%
Both reduce yoy usage, with AGEN at -28.38%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-230.77%
Both negative yoy AP, with AGEN at -194.59%. Martin Whitman would find an overall trend toward paying down supplier credit in the niche.
-79.38%
Both reduce yoy usage, with AGEN at -119.16%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
-151.83%
Both negative yoy, with AGEN at -92.90%. Martin Whitman would suspect an overall environment of intangible cleanup or shifting revaluations for the niche.
55.51%
Some CFO growth while AGEN is negative at -18.86%. John Neff would note a short-term liquidity lead over the competitor.
52.86%
Some CapEx rise while AGEN is negative at -15680.97%. John Neff would see competitor possibly building capacity while we hold back expansions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
52.86%
We have mild expansions while AGEN is negative at -15680.97%. John Neff sees competitor possibly divesting or pausing expansions more aggressively.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.